VivoSim gets a $5 million milestone payment from Eli Lilly, projects more than 500% FY2027 revenue growth

VivoSim, a developer of human-based preclinical testing tools, said it has received a $5 million milestone payment from Eli Lilly and Co. The payment is tied to the companies’ ongoing work, and VivoSim said it supports the company’s near-term cash position while it looks toward a rapid revenue ramp in the coming years.

In a market update circulated through Yahoo Finance, VivoSim also forecast “500%+” revenue growth for fiscal 2027. Management attributed the expected increase to expanding demand for its platform used in preclinical testing, where sponsors evaluate drug candidates before clinical trials in patients.

VivoSim’s platform is described in the post as “human-based” and aimed at preclinical work, a positioning that matters in biopharma research because many drug candidates can fail after earlier stages. Companies in the drug development ecosystem have been under pressure to improve translational accuracy, the ability for early test results to predict later outcomes. That broader market trend is one reason preclinical methodologies are a recurring area of spend by large pharmaceutical companies.

Eli Lilly, as a major pharmaceutical manufacturer, has increasingly relied on collaborations and enabling technologies to support drug discovery and development. However, the market update did not provide additional contract specifics such as the timeline of the milestone, the underlying performance criteria, or whether further payments are contingent on additional milestones.

The $5 million milestone payment, while modest compared with large pharma budgets, can be material for smaller biotech and enabling-technology firms as they fund platform development, validation work, and scaling activities. In the post, VivoSim linked the milestone to improved cash runway and to its ability to pursue the demand it expects into fiscal 2027.

VivoSim did not disclose, in the information carried in the circulated market update, any breakdown of the forecast into product lines, customer counts, or expected revenue drivers beyond the statement that demand for its platform is expanding. It also did not clarify whether the projected growth is driven by new deals, renewals, contract expansions, or a mix of these factors.

From a market perspective, a forward-looking projection of 500% or more revenue growth can announcement confidence in commercial traction, but it also raises questions about execution risk, particularly in preclinical services and technology adoption cycles. Biopharma preclinical work can involve long evaluation periods, protocol customization, and decision gates that may affect timing even when demand exists.

Investors and industry watchers will likely focus next on whether VivoSim can convert the expected demand into signed agreements and measurable revenue visibility as fiscal 2027 approaches. Additional disclosures on customer pipeline, the structure and economics of Lilly-related milestones, and any further milestone or royalty arrangements would help clarify how much of the forecast is already under contract versus dependent on future negotiations.